Integrated BioSci Investing: Latest Bioscience Breakthroughs

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Integrated BioSci Investing: CAR-T FDA Approved And Promising Developments

Summary

• CAR-TCR received FDA approval for the treatment of non-Hodgkin lymphoma.
• Kite, Exelixis, and Spectrum are delivering stellar returns for subscribers.
• We intend to increase the forecasting of both clinical and regulatory catalysts.
• Integrated BioSci Investing portfolio is yielding an overall robust return.

The biotech sector is highly promising with merger and acquisition to boost for stellar profits. In the past 52-weeks, Kite Pharma (NASDAQ:KITE) was acquired by Gilead Sciences Inc (NASDAQ:GILD) for $11.9B (on Aug. 28, 2017). This catapulted our portfolio’s profits on Kite to 82%. As this story is playing out, the FDA approved CAR-TCR as the treatment for non-Hodgkin lymphoma (on Oct. 18, 2017). The stellar news (for both patients and investors) gives further credence to our thesis on CAR-TCR (as a major breakthrough since the introduction of chemotherapy, half a decade prior).

Source: Google Finance

Biotech: The Big Payoff

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Kite Pharma: What Can Investors Learn From The Gilead Acquisition?

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Kite Pharma: How High Will It Fly?

Summary

• Engineered T cells therapy is showing highly promising early trials results as the next potential cancer breakthrough.
• After a twofold share price increase, the question remains whether such a growth trajectory will be sustained.
• The market value of a firm correlates with its intrinsic value, at least in the long haul, and thus we expect further upside in Kite Pharma.

Based in Santa Monica, California, Kite Pharma (NASDAQ: KITE) is dedicated to the delivery of cancer therapeutics through the innovative engineered T cell therapy ("ETCs") platform. With the dramatic results seen thus far in early clinical trials (and especially the cancer remission witnessed in refractory cases), the firm has reasons to pride itself as the leader in ETCs. This biotechnology can potentially deliver the biggest cancer treatment breakthrough since the introduction of chemotherapy more than half a century ago.

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.